dan 2163 has been researched along with Acute Disease in 20 studies
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both amisulpride and olanzapine produce sustained improvement in certain measures of neuropsychological performance in patients with schizophrenia; a significant improvement in score on the AVLT was observed only with amisulpride." | 9.12 | Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia. ( Balasubramaniam, K; Choudhary, PC; Joyce, E; Mortimer, AM; Saleem, PT, 2007) |
| "Amisulpride, a substituted benzamide with high selectivity for dopamine D3 and D2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia." | 9.09 | Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. ( Bale, R; Bech, P; Fleurot, O; Möller, HJ; Peuskens, J; Rein, W, 1999) |
| "Olanzapine has a related chemical structure and comparable receptor-binding profile as clozapine, which demonstrated superior efficacy in combination studies, but has a more unfavorable side-effect profile compared to olanzapine." | 6.94 | A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. ( Baumgärtner, J; Brockhaus-Dumke, A; Cordes, J; Correll, CU; Engelke, C; Englisch, S; Feyerabend, S; Gaebel, W; Gouzoulis-Mayfrank, E; Gründer, G; Hasan, A; Heres, S; Jäger, M; Kluge, M; Kolbe, H; Lange, C; Langguth, B; Leucht, S; Makiol, C; Meisenzahl-Lechner, E; Neff, A; Poeppl, T; Reske, D; Riesbeck, M; Schmidt-Kraepelin, C; Verde, PE; Wobrock, T; Zink, M, 2020) |
| "This 4-week, double-blind, randomized study was undertaken to determine the dose-response relationship of amisulpride in 319 patients with acute exacerbation of schizophrenia." | 6.69 | Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. ( Fleurot, O; Puech, A; Rein, W, 1998) |
| " This study aimed to compare the efficacy and safety of low-dose amisulpride plus low-dose sulpiride with full-dose amisulpride in the treatment of acute schizophrenia." | 5.17 | Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study. ( Chen, CC; Huang, YH; Lane, HY; Lin, CH; Lin, SC; Wang, FC, 2013) |
| "Both amisulpride and olanzapine produce sustained improvement in certain measures of neuropsychological performance in patients with schizophrenia; a significant improvement in score on the AVLT was observed only with amisulpride." | 5.12 | Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia. ( Balasubramaniam, K; Choudhary, PC; Joyce, E; Mortimer, AM; Saleem, PT, 2007) |
| "Amisulpride, a substituted benzamide with high selectivity for dopamine D3 and D2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia." | 5.09 | Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. ( Bale, R; Bech, P; Fleurot, O; Möller, HJ; Peuskens, J; Rein, W, 1999) |
| "Olanzapine has a related chemical structure and comparable receptor-binding profile as clozapine, which demonstrated superior efficacy in combination studies, but has a more unfavorable side-effect profile compared to olanzapine." | 2.94 | A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. ( Baumgärtner, J; Brockhaus-Dumke, A; Cordes, J; Correll, CU; Engelke, C; Englisch, S; Feyerabend, S; Gaebel, W; Gouzoulis-Mayfrank, E; Gründer, G; Hasan, A; Heres, S; Jäger, M; Kluge, M; Kolbe, H; Lange, C; Langguth, B; Leucht, S; Makiol, C; Meisenzahl-Lechner, E; Neff, A; Poeppl, T; Reske, D; Riesbeck, M; Schmidt-Kraepelin, C; Verde, PE; Wobrock, T; Zink, M, 2020) |
| "This 4-week, double-blind, randomized study was undertaken to determine the dose-response relationship of amisulpride in 319 patients with acute exacerbation of schizophrenia." | 2.69 | Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. ( Fleurot, O; Puech, A; Rein, W, 1998) |
| "In the long term treatment of schizophrenia, amisulpride maintained antipsychotic efficacy over a 12-month period in an open randomized study." | 2.41 | Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation? ( Blin, O, 2000) |
| " In patients with acute exacerbations of schizophrenia, the recommended dosage of amisulpride is 400 to 800 mg/day, although dosages < or =1200 mg/day may be administered." | 2.41 | Amisulpride: a review of its use in the management of schizophrenia. ( Curran, MP; Perry, CM, 2001) |
| "Acute psychosis is diagnosed by clearly defined operational criteria embedded into international classification systems." | 1.36 | Gender, psychosis and psychotropic drugs: differences and similarities. ( Groleger, U; Novak-Grubic, V, 2010) |
| "The acute phase of schizophrenia is characterized by the presence of positive, negative and affective symptoms." | 1.31 | Acute phase of schizophrenia: impact of atypical antipsychotics. ( Azorin, JM, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 10 (50.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schmidt-Kraepelin, C | 1 |
| Feyerabend, S | 1 |
| Engelke, C | 1 |
| Riesbeck, M | 1 |
| Meisenzahl-Lechner, E | 1 |
| Gaebel, W | 1 |
| Verde, PE | 1 |
| Kolbe, H | 1 |
| Correll, CU | 1 |
| Leucht, S | 2 |
| Heres, S | 1 |
| Kluge, M | 1 |
| Makiol, C | 1 |
| Neff, A | 1 |
| Lange, C | 1 |
| Englisch, S | 1 |
| Zink, M | 1 |
| Langguth, B | 1 |
| Poeppl, T | 1 |
| Reske, D | 1 |
| Gouzoulis-Mayfrank, E | 1 |
| Gründer, G | 1 |
| Hasan, A | 1 |
| Brockhaus-Dumke, A | 1 |
| Jäger, M | 1 |
| Baumgärtner, J | 1 |
| Wobrock, T | 1 |
| Cordes, J | 1 |
| Barrimi, M | 1 |
| El Ghazouani, F | 1 |
| Zaimi, O | 1 |
| Oneib, B | 1 |
| Suthar, N | 1 |
| Nebhinani, N | 1 |
| Mahawer, B | 1 |
| Gupta, T | 1 |
| Tripathi, S | 1 |
| Lin, CH | 1 |
| Wang, FC | 1 |
| Lin, SC | 1 |
| Huang, YH | 1 |
| Chen, CC | 1 |
| Lane, HY | 1 |
| Ebdrup, BH | 1 |
| Raghava, JM | 1 |
| Nielsen, MØ | 1 |
| Rostrup, E | 1 |
| Glenthøj, B | 1 |
| Ursini, F | 1 |
| Succurro, E | 1 |
| Grembiale, A | 1 |
| Arturi, F | 1 |
| Groleger, U | 1 |
| Novak-Grubic, V | 1 |
| Leweke, FM | 1 |
| Piomelli, D | 1 |
| Pahlisch, F | 1 |
| Muhl, D | 1 |
| Gerth, CW | 1 |
| Hoyer, C | 1 |
| Klosterkötter, J | 1 |
| Hellmich, M | 1 |
| Koethe, D | 1 |
| Mortimer, A | 1 |
| Martin, S | 1 |
| Lôo, H | 1 |
| Peuskens, J | 2 |
| Kane, JM | 1 |
| Kissling, W | 1 |
| Hamann, J | 1 |
| Etschel, E | 1 |
| Engel, R | 1 |
| Mortimer, AM | 1 |
| Joyce, E | 1 |
| Balasubramaniam, K | 1 |
| Choudhary, PC | 1 |
| Saleem, PT | 1 |
| Puech, A | 1 |
| Fleurot, O | 2 |
| Rein, W | 2 |
| Bech, P | 1 |
| Möller, HJ | 2 |
| Bale, R | 1 |
| Naber, D | 1 |
| Jatzko, A | 1 |
| Ries, S | 1 |
| Schreiner, A | 1 |
| Braus, DF | 1 |
| Azorin, JM | 1 |
| Blin, O | 1 |
| Cesková, E | 1 |
| Drybcák, P | 1 |
| Hrobar, P | 1 |
| Lorenc, M | 1 |
| Spacek, J | 1 |
| Curran, MP | 1 |
| Perry, CM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Comparison of the Efficacy and Safety of Olanzapine Versus Low-dose Olanzapine Plus Low-dose Trifluoperazine in the Treatment of Schizophrenia[NCT02704962] | Phase 4 | 94 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| [NCT01615185] | Phase 4 | 96 participants (Actual) | Interventional | 2008-01-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for dan 2163 and Acute Disease
| Article | Year |
|---|---|
Amisulpride: a review of its efficacy in schizophrenia.
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chronic Disease; C | 2000 |
Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation?
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Dose-Response Relationship, Drug; Humans; Psychiat | 2000 |
Amisulpride: a review of its use in the management of schizophrenia.
Topics: Acute Disease; Administration, Oral; Adsorption; Amisulpride; Antipsychotic Agents; Chronic Disease; | 2001 |
7 trials available for dan 2163 and Acute Disease
| Article | Year |
|---|---|
A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design.
Topics: Acute Disease; Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Double-Blind Method; Drug | 2020 |
Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Cost Savings; Diagnostic and Statistical Ma | 2013 |
Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Cost Savings; Diagnostic and Statistical Ma | 2013 |
Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Cost Savings; Diagnostic and Statistical Ma | 2013 |
Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Cost Savings; Diagnostic and Statistical Ma | 2013 |
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.
Topics: Acute Disease; Adult; Amides; Amisulpride; Antipsychotic Agents; Arachidonic Acids; Cannabidiol; Dou | 2012 |
A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brief Ps | 2004 |
Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dose- | 2007 |
Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Bl | 1998 |
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Body Weight; Double-Blind Method; Female; H | 1999 |
10 other studies available for dan 2163 and Acute Disease
| Article | Year |
|---|---|
[Neuroleptic malignant syndrome under amisulpride in a patient during a second acute psychotic episode].
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Female; Humans; Neuroleptic Malignant Syndr | 2018 |
Amisulpride induced acute dystonia.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Dystonia; Humans; Male; Young Adult | 2018 |
Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.
Topics: Acute Disease; Adult; Amisulpride; Anisotropy; Antipsychotic Agents; Brain; Diffusion Magnetic Reson | 2016 |
Acute rhabdomyolysis during treatment with amisulpride and metformin.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Biomarkers; Creatine Kinase, MM Form; Human | 2010 |
Gender, psychosis and psychotropic drugs: differences and similarities.
Topics: Acute Disease; Adult; Affect; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain; Dose-Respon | 2010 |
Clinical implications of Brief Psychiatric Rating Scale scores.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olan | 2005 |
[Atypical antipsychotics].
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; | 2000 |
[Acute tongue and pharyngeal spasms during changeover from clozapine to amisulpride. A case example].
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Clozapine; Drug Administration Schedule; Dr | 2000 |
Acute phase of schizophrenia: impact of atypical antipsychotics.
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Haloperidol; Humans; Prognosis; Recurrence; Risper | 2000 |
The changes of biological markers and treatment efficacy in schizophrenia.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Biomarkers; Brain; Cognition; Dexamethasone | 2001 |